Stemas s.r.l. Competitors

Biolife, a wholly owned subsidiary of Merit Medical, is medical device company in Sarasota, Florida, that manufactures innovative healthcare and first aid solutions that improve patient care and outcomes. All Biolife products are comprised of a powder with two main ingredients: potassium ferrate and a hydrophilic, or water loving, polymer. StatSeal devices for the healthcare industry are available in both powder and disc form; the disc is made of compressed powder that is encased in a white medical-grade foam. WoundSeal devices for the consumer and occupational health industries are available in powder form. All Biolife devices are manual pressure adjuncts and work via a two-step mechanism of action that occurs simultaneously to form a low pH seal or physical barrier over the wound, protecting it by letting nothing in or nothing out. The hydrophilic polymer rapidly dehydrates the blood and absorbs exudate, stacking up desiccated blood solids beneath to form a seal (scab). The potassium ferrate binds the blood solids and proteins together, adhering the seal (scab) to the wound to stop bleeding and oozing. Beneath the seal, the pH is neutral and blood solids and proteins continue to stack naturally. Above the seal the hydrophilic polymer acts as a desiccant and creates an acidic environment with a pH of ~ 2. All Biolife devices work independently of the clotting cascade to create an occlusive seal over the wound or procedural site, while accelerating hemostasis and helping to improve recovery time. The seal remains over the wound as the body’s healing mechanism begins. As the wound heals, the scab is naturally sloughed off.

Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PSTI/PLTR) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. Pluristem’s PLacental eXpanded (PLX) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. These cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. The Company’s proprietary, 3D expansion technology can be used to grow PLX cells in mass quantities with batch-to-batch consistency at Pluristem’s FDA, EMA and PMDA-approved, state-of-the art manufacturing facility. Pluristem’s first product candidate is PLX-PAD, a cell therapy product for the treatment of tissues that have been damaged by ischemia, muscle trauma, or inflammation. Pluristem’s second cell therapy product in development, PLX-R18, is designed to treat hematological conditions including ARS, insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT) , certain cancers or cancer treatments

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.